Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
FAM83C antisense RNA 1 (FAM83C-AS1) is a long non-coding antisense RNA that regulates gene expression through epigenetic mechanisms. It is notably upregulated in colorectal cancer, where it promotes tumor cell proliferation, migration, invasion, and stemness. Mechanistically, FAM83C-AS1 inhibits expression of the tumor suppressor Semaphorin 3F (SEMA3F) by enhancing H3K27me3 methylation at the SEMA3F promoter through stabilization of the methyltransferase EZH2, which is facilitated by recruitment of the deubiquitinase ZRANB1. In experimental models, knockdown of FAM83C-AS1 reduces tumor growth, metastasis, and EMT, highlighting its functional contribution to cancer progression and its potential as a therapeutic and biomarker target. Currently, no approved drugs directly target FAM83C-AS1, but antisense technologies and RNA interference are the main experimental approaches. FAM83C-AS1 is considered a valid molecular target in oncology research, with increasing evidence supporting its role in colorectal cancer and potentially other malignancies.
Silencing by RNA interference or antisense oligonucleotides is under investigation as a potential therapeutic strategy. Knockdown leads to suppression of tumor growth and metastasis in preclinical models. FAM83C-AS1 binds ZRANB1, increasing EZH2 stability. EZH2 catalyzes H3K27me3 methylation on SEMA3F promoter, suppressing SEMA3F. Reduced SEMA3F leads to enhanced colorectal cancer cell growth and invasiveness. Knockdown of FAM83C-AS1 reverses these effects.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Family with sequence similarity 83 member C antisense RNA 1 (FAM83C-AS1).